Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2016. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibilities (PDMRs), and Connected Persons under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific share plan transactions:
- Ordinary Share Price: 1,380.50 pence per share.
- ADS Price: $40.28 per American Depositary Share.
- Transaction Type: Notional acquisition of shares following the re-investment of dividends paid on January 14, 2016.
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It strictly details the notional share acquisitions by specific individuals as part of a dividend re-investment mechanism.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Plan holdings that vest following the end of the relevant measurement period.
Investor Verification Checklist
- Verify the vesting schedule and measurement period for the 2009 Performance Share Plan to understand future payout obligations.
- Confirm the total number of notional shares acquired by Sir Andrew Witty (19,386.598 Ordinary Shares) and other key executives.
- Review the dividend payment date of January 14, 2016, to correlate with the re-investment pricing.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial results.